The methylation level of the FOXP1 gene promoter region was significantly lower in the AML samples compared to samples from patients with MDS and normal controls (P<0.001 and P<0.05, respectively) (Figures 3A, B). Here, FOXP1 is linked to myelodysplastic syndrome.